Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/00, \ 30/09/01, \ 11/o3/02, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$

Name of entity

ELK PETROLEUM LTD

ABN	
38 112 566 499	
We (the entity) give ASX the follow	owing information.
Part 1 - All issues You must complete the relevant sections	(attach sheets if there is not enough space).
*Class of *securities issued or to be issued	Convertible Loan Facility (ELKAN) – agreement to potentially issue ordinary shares
Number of *securities issued or to be issued (if known) or maximum number which may be issued	Number of potential ordinary shares to be issued: 6,387,328

Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

Terms of Convertible Loan Facility at fixed conversion of 0.76 exchange rate:

Facility Amount:

US\$500,000 (out of maximum of US\$10,028,210, remaining unissued balance of US\$148,210) or AUD\$657,895 (out of maximum of AUD\$13,195,013, remaining unissued balance of AUD\$195,013)

Interest Rate:

11% per annum

Conversion Rate:

The Convertible Loan Facility may be converted into ordinary shares, unless repaid by Elk Petroleum Limited.

Maturity Date:

31 March 2020

Conversion Price and Period:

- AUD\$0.103 / 10.3 cents (for the total sum of US\$500,000)
- one third of the Facility Amount, can be converted from the period commencing 31 March 2018
- half of the remaining Facility Amount, can be converted from the period commencing 31 March 2019
- the remaining Facility Amount, can be converted from 30 days prior to 31 March 2020

Early Repayment Premium:

The Borrower can make an early repayment and if this repayment is made before 31 December 2018, the repayment must equal 120% of the principal amount repaid.

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

No, not listed however convertible loan facility is ELKAN class.

Yes, in relation to the shares to be issued upon conversion of the Convertible Loan Facility will be fully paid and rank equally with the fully paid ordinary shares on issue on the date of conversion.

5 Issue price or consideration

Total AUD\$657,895 (out of total facility of AUD\$13,195,013, remaining unissued balance of AUD\$195,013)

(US\$500,000 out of total facility of US\$10,028,210, remaining unissued balance of US\$148,210)

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

The funds will be used to acquire Madden Gas Field and Lost Cabin Gas Plant from Freeport McMoRan.

6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h *in* relation to the +securities the subject of this Appendix 3B, and comply with section 6i

- --

6b The date the security holder resolution under rule 7.1A was passed

28 November 2016

6c Number of *securities issued without security holder approval under rule 7.1

Number of potential ordinary shares to be issued: 6,387,328

6d Number of *securities issued with security holder approval under rule 7.1A

Nil

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of *securities issued under an exception in rule 7.2	Nil	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer to annexure 1	
7	⁺ Issue dates	7 April 2017	
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	7 T.p. 11 2017	
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and *class of all *securities quoted on ASX (<i>including</i> the *securities in section 2 if applicable)	854,046,208	Ordinary shares (ASX:ELK)
		22,675,000	Listed Options, Exercise Price \$0.25, Expiry date 22/07/2017 (ASX: ELKO)

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
719,680	Retention Rights
719,000	Conversion Price -
	VWAP over 20 days
	prior to and
	including 30 June
	2017
183,595	Retention Rights
	Conversion Price -
	VWAP over 20 days
	prior to and
	including 30 June
	2010
475,000	Retention Rights
	Conversion Price – VWAP over 20 days
	prior to and
	including 30 June
	2019
1,378,275	Total Class - ELKAI
1,378,275 4,000,000	
	Total Class - ELKAI
4,000,000	Total Class - ELKAI Performance Rights CEO
	Total Class - ELKAI Performance Rights
4,000,000	Total Class - ELKAI Performance Rights CEO Performance Rights
4,000,000	Performance Rights CEO Performance Rights Conversion Price –
4,000,000 2,833,119	Performance Rights CEO Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2017
4,000,000	Performance Rights CEO Performance Rights Conversion Price – VWAP over 20 days
4,000,000 2,833,119	Performance Rights CEO Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2017 Performance Rights
4,000,000 2,833,119	Performance Rights CEO Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2017 Performance Rights Conversion Price –
4,000,000 2,833,119	Performance Rights CEO Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2017 Performance Rights Conversion Price – VWAP over 20 days
4,000,000 2,833,119 1,870,000	Performance Rights CEO Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2017 Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2018
4,000,000 2,833,119	Performance Rights CEO Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2017 Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2018 Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2018
4,000,000 2,833,119 1,870,000	Performance Rights CEO Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2017 Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2018 Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2018
4,000,000 2,833,119 1,870,000	Performance Rights CEO Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2017 Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2018 Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2018
4,000,000 2,833,119 1,870,000	Performance Rights CEO Performance Rights CEO Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2017 Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2018 Performance Rights Conversion Price – VWAP over 20 days prior to 30 June 2018

		1,333,333	Balance Options (Unlisted) over unissued ordinary shares (ELKAM)
		Agreement to issue up to: 119,826,264 shares + 6,387,328 126,213,592	Convertible Loan
			Facility (ELKAN)
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	
Part	2 - Pro rata issue		
11	Is security holder approval required?		
12	Is the issue renounceable or non-renounceable?		
13	Ratio in which the *securities will be offered		
14	⁺ Class of ⁺ securities to which the offer relates		
15	⁺ Record date to determine entitlements		
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?		
17	Policy for deciding entitlements in relation to fractions		

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
10	Closing date for receipt of	
19	acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
22	Eas or commission payable to the	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on	
25	security holders' approval, the date of the meeting	
-6	Date entitlement and acceptance	
26	form and offer documents will be sent to persons entitled	
	TC 1 1 1	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
- 0	Deta wishes and 10 - 211 1 - 1 - 00	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if	
	applicable)	
		_
30	How do security holders sell	

	their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	⁺ Issue date	
	t 3 - Quotation of securit	
34	Type of *securities (tick one)	
(a)	+Securities described in Part	t 1
(b)	•	end of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
	ies that have ticked box 34(a)	
	o indicate you are providing the informat	
35	1 1	securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36		y securities, a distribution schedule of the additional umber of holders in the categories
37	A copy of any trust deed for	the additional *securities

+ See chapter 19 for defined terms.

Appendix 3B Page 8 04/03/2013

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the teacywities rank equally in		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state: 1. the date from which they do 2. the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment 3. the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in clause 38)	Number	+Class

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	(Joint Company secretary)	Date: 7 April 2017
Print name:	David Franks	
	== == == ==	

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	277,003,900	
Add the following:		
Number of fully paid ⁺ ordinary securities issued in that 12 month period under an exception in rule 7.2	410,073,919	
Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval	166,968,389	
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period	0	
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	0	
"A"	854,046,208	

04/03/2013 Appendix 3B Page 11

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	128,106,931	
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule	
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	128,106,923	
Under an exception in rule 7.2		
Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	128,106,923	
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15	128,106,931	
Note: number must be same as shown in Step 2		
Subtract "C"	126,213,592	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	1,893,339	
	[Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

from which the placement 4,046,208 0 te: this value cannot be changed 404,620		
0 te: this value cannot be changed		
te: this value cannot be changed		
te: this value cannot be changed		
te: this value cannot be changed		
ū .		
404 620		
707,020		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		

04/03/2013 Appendix 3B Page 13

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	85,404,620	
Note: number must be same as shown in Step 2		
Subtract "E"	0	
Note: number must be same as shown in Step 3		
Total ["A" x 0.10] – "E"	85,404,620	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 14 04/03/2013

⁺ See chapter 19 for defined terms.